EmbeddingGemma 2: an open, lightweight multimodal embedding model
deepmind.google·6d ago
AI Engineering
MIT Technology Review·Jul 31·5 min read
The Download: Montana’s new experimental drug rules
TL;DR
Montana has introduced a new framework allowing biotech companies to fast-track experimental drug approvals for a fee, potentially transforming the state into a medical innovation hub. This legislation enables access to treatments for anyone who can pay and provides informed consent, sparking both excitement and ethical concerns.
✦ Why It Matters
Consider exploring opportunities in biotech or experimental treatments if you are in the medical or tech fields.
Key Takeaways
- Understand the implications of Montana's right-to-try law for drug access.
- Evaluate the ethical considerations of experimental drug sales.
- Stay informed about upcoming experimental treatment clinics in Montana.
- Engage in discussions about patient rights and drug safety.
Full Summary
Montana's recent legislation allows biotech firms to apply for approval to sell experimental drugs after preliminary testing, which can involve as few as 10 healthy individuals. Companies can pay $12,500 to a newly formed review board for this approval, with the first experimental treatment clinics expected to open by the end of the year.
This 'right-to-try' law theoretically grants access to anyone who can pay and provides informed consent, offering hope to patients with rare conditions like creatine transporter deficiency. However, critics argue that this approach could lead to unethical practices and unsafe treatments.
The case of Kris DeVault, whose son suffers from a rare condition, highlights the desperate need for such access, despite the risks involved. The implications of this law could reshape how experimental drugs are accessed and regulated in the U.S.